Skip to main content

Significant itch improvement

PRIME 18+ YEARS

Proportion of patients with ≥4-point
improvement in WI-NRS AT WEEK 24

(primary endpoint)1-3,a
  • A nominal difference was observed at Week 4 (19% with DUPIXENT vs 4% with placebo)3

Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.

PRIME2 18+ YEARS

  • A nominal difference was observed at Week 11 (33% with DUPIXENT vs 17% with placebo), with a significantly greater proportion of DUPIXENT patients achieving a meaningful response at Week 12 (37% with DUPIXENT vs 22% with placebo; P=0.022, primary endpoint). At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo (P <0.001, secondary endpoint)1-3

Definitive conclusions cannot be made for results at timepoints other than Week 12 and 24 in PRIME2. Data were not multiplicity controlled.

PRIME and PRIME2
Pooled analysis
Itch improvement observed after first dose (as measured at Week 2)4
  • 7.8% of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 2 vs 1.9% with placebo3,4
  • 59% of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 24 vs 19% with placebo3,4

Definitive conclusions cannot be made for these results as the data were not multiplicity controlled and P values were nominal.

DUPIXENT showed consistent efficacy regardless of patients’ atopic background1,5

PRIME and PRIME2
Pooled analysis

Itch improvement regardless of patients’ history of atopy

Proportion of patients with ≥4-point improvement in WI-NRS at Week 241,5

Definitive conclusions cannot be made for these results as the data were not
multiplicity controlled and P values were nominal.

In the PRIME trials, patients were stratified by their history of atopy.

PN is a chronic and distinct dermatologic disease
57 percent
of patients across PRIME and PRIME2 did not have a history of atopy (defined as having a medical history of atopic dermatitis, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy)1

IGA PN-S, Investigator’s Global Assessment PN-Stage; PN, prurigo nodularis; Q2W, once every 2 weeks; SD, standard deviation; WI-NRS, Worst Itch numerical rating scale.

EXPLORE NODULE
CLEARANCE

VIEW IGA PN-S RESULTS